

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6045357

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| AVENTIS PHARMA S.A. | 04/03/2020 |
| RECEIVING PARTY DATA | |
| Name: | SANOFI MATURE IP |
| Street Address: | 54 RUE LA BOETIE |
| City: | PARIS |
| State/Country: | FRANCE |
| Postal Code: | 75008 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 16743411 |
| CORRESPONDENCE DATA | |
| Fax Number: | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Email: | sanofi-patents@docket.cpaglobal.com |
| Correspondent Name: | SANOFI IP DEPT. |
| Address Line 1: | 55 CORPORATE DRIVE |
| Address Line 2: | 55A-505A |
| Address Line 4: | BRIDGEWATER, NEW JERSEY 08807 |
| ATTORNEY DOCKET NUMBER: | FR2009/121-US-CNT5 |
| NAME OF SUBMITTER: | MARIJKE ABBES |
| SIGNATURE: | /Marijke Abbes/ |
| DATE SIGNED: | 04/03/2020 |
| Total Attachments: 1 | |
| source=Assignment-20200403#page1.tif | |

ASSIGNMENT

For valuable consideration, the receipt of which is hereby acknowledged, and intending to be bound legally, **AVENTIS PHARMA S.A.**, a corporation formed under the laws of France and having a principal place of business at 20 avenue Raymond Aron, 92169 ANTONY, FRANCE, (the "Assignor"), assigns to **SANOFI MATURE IP**, a corporation formed under the laws of France and having a principal place of business at 54 rue La Boétie, 75008 PARIS, FRANCE, and its successors, transferees, and assignees (collectively the "Assignee"), all of its right, title, and interest throughout the world in the subject matter (the "Subject Matter") disclosed or claimed in US patent application 16/743,411 that is titled "NOVEL ANTITUMORAL USE OF CABAZITAXEL", and was filed on January 15, 2020 (the "Application(s)").

This Assignment, effective as of November 30, 2018, assigns (a) the Application and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Applications and Granted Rights") in every country or region, (b) the right to claim priority based on and the benefit of the filing date of any of the Applications and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment.

Assignor authorizes the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Applications and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in the Assignor's name or in the Assignee's name.

Assignor represents and warrants that it has the right and power to make this Assignment and that it has not made and will not make any other assignment that conflicts with this Assignment.

Assignor will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.


Signed at PARIS on this 03 day of APRIL, 2020.

AVENTIS PHARMA S.A.

By: 
Name, Title: Muriel MOREL-PECHEUX, Authorized Signatory

ASSIGNMENT OF RIGHTS ACCEPTED BY SANOFI MATURE IP

Signed at PARIS on this 03 day of APRIL, 2020.

By: 
Name, Title: Catherine VAN ECK, Authorized Signatory

Assignment Page 1 of 1

PATENT